Stevanato Group NYSE: STVN reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary.
Stevanato (STVN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Franco Stevanato CEO | XMUN Exchange | IT0005452658 ISIN |
| IT Country | 6,010 Employees | 11 Jun 2026 Last Dividend | - Last Split | 16 Jul 2021 IPO Date |
Stevanato Group S.p.A. is an influential entity specializing in the design, production, and distribution of a broad range of products and services tailored for the bio-pharma and healthcare industries. Established in 1949 and operating out of Piombino Dese, Italy, the company plays a pivotal role across various global markets including Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. Stevanato Group operates through two main business segments: Biopharmaceutical and Diagnostic Solutions; and Engineering. It stands as a key subsidiary of Stevanato Holding S.R.L., demonstrating a longstanding commitment to innovation and quality in the healthcare sector.